China’s Hainan Haiyao Co has signed a letter of intent with Creator Investment and Good Catch Investments Limited, respectively for the acquisition of 250,564 common shares and 871,382 A preferred shares of SinoMab Bioscience, a Hong Kong-based company with offices and manufacturing facilities in Shenzhen.

n completion, Hainan Haiyao will hold a 40% stake in the SinoMab, which is seeking to discover therapeutic antibodies that treat life-threatening and debilitating diseases. Terms of the proposed transaction were not disclosed.

Enjoying this article? Have the leading Biopharma news & analysis delivered daily on email by signing up for our FREE email newsletter here.

Hainan Haiyao also announced recently that it will invest $2.1 million to set up a joint venture named Hudson Biopharma in the USA with Ding Qingjie, with each to hold a 70% and a 30% stake. The joint venture will be with a registered capital of $3 million and be engaged in the research, development and sale of medicine.

bioMerieux and Quanterix sign strategic partnership in ultrasensitive and multiplex immunoassays

Separately, France’s bioMerieux (Euronext: BIM) and the USA’s Quanterix have entered into a strategic agreement that gives bioMerieux worldwide exclusive rights to Quanterix’ Simoa technology in clinical laboratories and for industrial applications. Under the accord, Quanterix will deliver a new instrument and consumables based on its Simoa technology. bioMerieux will develop ultra-sensitive and multiplex assays on the platform.

At the same time, Quanterix has closed an $18.5 million Series C financing with participation from all existing investors, including ARCH Venture Partners, Bain Capital Ventures and Flagship Ventures, and joined by In-Q-Tel. bioMerieux has taken an initial $15 million equity stake in Quanterix.

Under the terms of the deal, Quanterix will receive upfront and milestone payments, as well as royalties on future sales. bioMerieux will take an additional equity stake, contingent on milestone achievement. In connection with the equity stake, bioMerieux has the right to designate one director for election to the Quanterix board. No further financial details of the transaction were disclosed.

SOURCE: thepharmaletter.com

 
 
 
 

  

Editorial Message 

This site contains materials from other clearly stated media sources for the purpose of discussion stimulation and content enrichment among our members only. 
whatsonsanya.com does not necessarily endorse their views or the accuracy of their content. For copyright infringement issues please contact editor@whatsonsanya.com